BioPort exacerbated the mistrust after multiple run-ins with the FDA and after news spread of its strong financial ties to military brass. On top of these problems, one month after DOD launched its mandatory program, BioPort stopped production to renovate its facilities to meet FDA standards, which explains why the stockpile of anthrax vaccine has dwindled to a trivial amount. But why has the government not contracted with other companies to make the vaccine? Why has the public not created a commercial market that would lead vaccine makers into the arena on their own? And why has so little research been devoted to understanding this disease and formulating an even better vaccine? These are deeper, more difficult questions.